Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk Timmerman

Showing results (201-210 of 222) with videos related to

Pageof 23
Sort By:
British Journal of Cancer|January 19, 2024
Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgeryChiara Landolfo, Jolien Ceusters, Lil Valentin, et al.
BMJ (Clinical Research Ed.)|January 28, 2026
Diagnostic tests for ovarian cancer in premenopausal women with non-specific symptoms (ROCkeTS): prospective, multicentre, cohort studySudha Sundar, Ridhi Agarwal, Katie Scandrett, et al.
Fertility and Sterility|November 15, 2024
An umbrella review of meta-analyses regarding the incidence of female-specific malignancies after fertility treatmentSrdjan Saso, Jen F Barcroft, Lorraine S Kasaven, et al.
NPJ Precision Oncology|December 11, 2025
ADNEX-AI: automated extraction of ultrasound predictors for interpretable ovarian cancer risk stratificationAxel Geysels, Giulia Garofalo, Stefan Timmerman, et al.
Human Reproduction (Oxford, England)|November 6, 2015
The Thessaloniki ESHRE/ESGE consensus on diagnosis of female genital anomaliesGrigoris F Grimbizis, Attilio Di Spiezio Sardo, Sotirios H Saravelos, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancerJenny Sprooten, Ann Vankerckhoven, Isaure Vanmeerbeek, et al.
Journal of Oncology|July 14, 2020
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in <i>BRCA1/2</i>: A Review of Secondary Prevention GuidelinesBoudewijn Dullens, Robin de Putter, Matteo Lambertini, et al.
Nature Cell Biology|August 3, 2019
Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screeningMatteo Boretto, Nina Maenhoudt, Xinlong Luo, et al.
Radiology|November 6, 2019
O-RADS US Risk Stratification and Management System: A Consensus Guideline from the ACR Ovarian-Adnexal Reporting and Data System CommitteeRochelle F Andreotti, Dirk Timmerman, Lori M Strachowski, et al.
Breast Cancer Research and Treatment|February 12, 2008
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positiveBen Van Calster, Isabelle Vanden Bempt, Maria Drijkoningen, et al.
Pageof 23

Showing results (201-210 of 222) with videos related to

Sort By:
Pageof 23
British Journal of Cancer|January 19, 2024
Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgeryChiara Landolfo, Jolien Ceusters, Lil Valentin, et al.
BMJ (Clinical Research Ed.)|January 28, 2026
Diagnostic tests for ovarian cancer in premenopausal women with non-specific symptoms (ROCkeTS): prospective, multicentre, cohort studySudha Sundar, Ridhi Agarwal, Katie Scandrett, et al.
Fertility and Sterility|November 15, 2024
An umbrella review of meta-analyses regarding the incidence of female-specific malignancies after fertility treatmentSrdjan Saso, Jen F Barcroft, Lorraine S Kasaven, et al.
NPJ Precision Oncology|December 11, 2025
ADNEX-AI: automated extraction of ultrasound predictors for interpretable ovarian cancer risk stratificationAxel Geysels, Giulia Garofalo, Stefan Timmerman, et al.
Human Reproduction (Oxford, England)|November 6, 2015
The Thessaloniki ESHRE/ESGE consensus on diagnosis of female genital anomaliesGrigoris F Grimbizis, Attilio Di Spiezio Sardo, Sotirios H Saravelos, et al.
Journal for Immunotherapy of Cancer|November 19, 2021
Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancerJenny Sprooten, Ann Vankerckhoven, Isaure Vanmeerbeek, et al.
Journal of Oncology|July 14, 2020
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in <i>BRCA1/2</i>: A Review of Secondary Prevention GuidelinesBoudewijn Dullens, Robin de Putter, Matteo Lambertini, et al.
Nature Cell Biology|August 3, 2019
Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screeningMatteo Boretto, Nina Maenhoudt, Xinlong Luo, et al.
Radiology|November 6, 2019
O-RADS US Risk Stratification and Management System: A Consensus Guideline from the ACR Ovarian-Adnexal Reporting and Data System CommitteeRochelle F Andreotti, Dirk Timmerman, Lori M Strachowski, et al.
Breast Cancer Research and Treatment|February 12, 2008
Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positiveBen Van Calster, Isabelle Vanden Bempt, Maria Drijkoningen, et al.
Pageof 23